New Delhi News

Presbyopia Pipeline Analysis Demonstrates Novel 12+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

 Breaking News
  • No posts were found

Presbyopia Pipeline Analysis Demonstrates Novel 12+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

March 16
23:54 2023
Presbyopia Pipeline Analysis Demonstrates Novel 12+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

DelveInsight’s, “Presbyopia Pipeline Insight, 2023,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Presbyopia Emerging drugs, the Presbyopia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Presbyopia pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Presbyopia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Presbyopia clinical trials studies, Presbyopia NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Presbyopia Pipeline Report

 

  • Presbyopia Pipeline report offers a comprehensive analysis of 12+ key pharma players and 12+key pipeline therapies.

 

  • The leading Presbyopia Companies include Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.

 

  • Promising Presbyopia Pipeline Therapies include UNR844-Cl, LaserACE(R), Pilocarpine, AGN-190584, CSF-1, and others.

 

  • The Presbyopia Companies and academics that are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The Presbyopia pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Request a sample and discover the recent breakthroughs happening in the Presbyopia Pipeline landscape @ Presbyopia Pipeline Outlook Report

 

Presbyopia Overview

Presbyopia is a vision condition in which the shape of the crystalline lens of your eye changes. These changes make it difficult to focus on close objects. Presbyopia may seem to occur suddenly, but sight reduction occurs over several years. Presbyopia usually becomes noticeable in the early to mid-40s, but the reduction of your focus starts as early as childhood. Some signs of presbyopia include holding reading materials at arm’s length, blurred vision at normal reading distance and eye fatigue along with headaches when doing close work.

 

Recent Developmental Activities in the Presbyopia Treatment Landscape

 

  • In August 2020, Eyenovia entered into an exclusive license agreement with Arctic Vision to develop and commercialize MicroPine (Atropine micro formulation) and MicroLine (pilocarpine micro formulation) in China, Hong Kong, Macau and Taiwan and South Korea.

 

  • In February 2021, Allergan submitted a New Drug Application to the Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.

 

For further information, refer to the detailed Presbyopia Drugs Launch, Presbyopia Developmental Activities, and Presbyopia News, click here for Presbyopia Ongoing Clinical Trial Analysis

 

Presbyopia Emerging Drugs Profile

 

  • CSF-1: Orasis Pharmaceuticals

CSF-1 is a novel presbyopia corrective eye drop being developed to improve the quality of life for people with presbyopia. CSF-1 is a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle. Clinical trial results to date have demonstrated significant improvements in near vision and an excellent safety profile in people with presbyopia. In the Phase 3 studies, CSF-1 achieved statistically significant distance-corrected near visual acuity (DCNVA) and no loss of 1-line or more in distance or night vision.

 

  • UNR844-Cl: Novartis

UNR844-Cl is an ester of naturally occurring R-lipoic acid and choline. Previously called EV06 ophthalmic solution, UNR844 targets directly the flexibility and accommodative ability of the crystalline lens. It breaks disulfide bonds, which are thought to harden the lens over time. By disrupting these bonds, the lens becomes more elastic and regains some functionality.

 

Presbyopia Pipeline Therapeutics Assessment

There are approx. 12+ key companies which are developing the therapies for Presbyopia. The companies which have their Presbyopia drug candidates in the most advanced stage, i.e. phase III include, Orasis Pharmaceuticals.

 

Find out more about the Presbyopia Pipeline Segmentation, Therapeutics Assessment, and Presbyopia Emerging Drugs @ Presbyopia Treatment Landscape

 

Scope of the Presbyopia Pipeline Report

 

  • Coverage- Global

 

  • Presbyopia Companies- Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.

 

  • Presbyopia Pipeline Therapies include UNR844-Cl, LaserACE(R), Pilocarpine, AGN-190584, CSF-1, and others.

 

  • Presbyopia Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Presbyopia Pipeline Companies and Therapies, click here @ Presbyopia Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Presbyopia: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Presbyopia – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. CSF-1: Orasis Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. UNR844-Cl: Novartis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Presbyopia Key Companies
  21. Presbyopia Key Products
  22. Presbyopia- Unmet Needs
  23. Presbyopia- Market Drivers and Barriers
  24. Presbyopia- Future Perspectives and Conclusion
  25. Presbyopia Analyst Views
  26. Presbyopia Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Presbyopia Mergers and acquisitions, Presbyopia Licensing Activities @ Presbyopia Recent Trends, and Future Perspectives 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles